Skip to main
MDXG
MDXG logo

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group Inc has demonstrated robust financial performance, achieving a 13% year-over-year revenue growth, with total revenues reported at $98.6 million driven significantly by both the wound care and surgical segments. The wound portfolio increased by 12% to $64.5 million, while the surgical business saw a 15% increase to $34.1 million, indicating strong demand and market positioning in its targeted sectors. Additionally, the company's upward revision of its 2025 revenue estimate to $387.3 million reflects positive momentum, backed by strong performance in the second quarter of 2025.

Bears say

MiMedx Group Inc. has experienced a decline in gross margin, decreasing to approximately 81% from 83% in the second quarter of 2025, primarily due to production variances and product mix, which may indicate underlying operational inefficiencies. Although the company aims for low double-digit year-over-year revenue growth and an adjusted EBITDA margin exceeding 20% in the long term, the pressure on margins raises concerns about its ability to achieve such targets consistently. Furthermore, potential adverse changes in reimbursement rates from CMS could significantly impact the company’s revenue trajectory, adding additional risks to its financial outlook.

MiMedx Group (MDXG) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 1 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.